Latest & greatest articles for ramipril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ramipril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ramipril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ramipril

1. Ramipril

Ramipril Top results for ramipril - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ramipril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. [Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?].

[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?]. 25774586 2015 03 17 2016 10 18 2016 12 30 1724-5990 32 1 2015 Jan-Feb Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia G Ital Nefrol [Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?]. gin/32.1.9 Ramipril administered once daily is characterized by an attenuation of its pharmacological activity in the following (...) 24 hours, whose effects on antiproteinuric activity have not yet been investigated. The antiproteinuric efficacy of Ramipril has been evaluated in a cross-over study in 20 patients with renal disease, proteinuria and hypertension (GFR50 mL / min, proteinuria <3 g / day; SBP/DBP 150/90 mmHg). Proteinuria was measured over 24 hours on three consecutive urine collections (morning, afternoon and night) in the absence of antiproteinuric drugs and after ten days of treatment with single morning

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia2015

3. Symptoms of peripheral arterial disease: ramipril

Symptoms of peripheral arterial disease: ramipril Symptoms of peripher Symptoms of peripheral arterial disease: r al arterial disease: ramipril amipril Evidence summary Published: 30 June 2015 nice.org.uk/guidance/esuom45 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in June 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information (...) . Summary The evidence for the efficacy of ramipril in relieving the symptoms of peripheral arterial disease is very limited. Two small RCTs (Ahimastos et al. 2006, n=40 and Shahin et al. 2013a, n=33) found that, compared with placebo, over 24 weeks, ramipril 10 mg daily improved maximum and pain-free walking times and distances in people with stable intermittent claudication, a symptom of peripheral arterial disease. However, while these differences were statistically significant, the clinical

National Institute for Health and Clinical Excellence - Advice2015

4. Ramipril for claudication?

Ramipril for claudication? Ramipril for claudication? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Ramipril for claudication? View/ Open Date 2013-10 Format Metadata Abstract This ACE inhibitor can help patients with peripheral artery disease walk longer while remaining pain free. URI Part of Citation Journal

PURLS2014

5. Randomised controlled trial: Ramipril improves walking times and quality of life in patients with stable intermittent claudication

Randomised controlled trial: Ramipril improves walking times and quality of life in patients with stable intermittent claudication Ramipril improves walking times and quality of life in patients with stable intermittent claudication | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ramipril improves walking times and quality of life in patients with stable intermittent claudication Article Text Therapeutics Randomised controlled trial Ramipril improves walking times and quality of life in patients with stable intermittent claudication Julie Brittenden

Evidence-Based Medicine (Requires free registration)2014

6. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.

Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. 23385271 2013 02 06 2013 02 07 2016 10 17 1538-3598 309 5 2013 Feb 06 JAMA JAMA Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. 453-60 10.1001/jama.2012.216237 Approximately one-third of patients with peripheral artery (...) disease experience intermittent claudication, with consequent loss of quality of life. To determine the efficacy of ramipril for improving walking ability, patient-perceived walking performance, and quality of life in patients with claudication. Randomized, double-blind, placebo-controlled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] years), initiated in May 2008 and completed in August 2011 and conducted at 3 hospitals in Australia. Patients were

JAMA2013

7. Ramipril 2.5 mg/5 ml oral solution

Ramipril 2.5 mg/5 ml oral solution Ramipril 2.5 mg/5 ml oral solution Ramipril 2.5 mg/5 ml oral solution All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Ramipril 2.5 mg/5 ml oral solution. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All (...) Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2612. 2012 Authors' conclusions Ramipril oral solution is recommended as an option for use within NHS Wales for: - Treatment of hypertension. - Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease); - diabetes with at least one cardiovascular

Health Technology Assessment (HTA) Database.2012

8. Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal 21515846 2011 05 27 2011 09 23 2016 12 15 1935-5548 34 6 2011 Jun Diabetes care Diabetes Care Incidence of diabetes following ramipril or rosiglitazone withdrawal. 1265-9 10.2337/dc10-1567 To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. The 3,366 DREAM subjects at trial (...) end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. Following median (interquartile range) 71 (63-86) days drug withdrawal, overall glycemic status remained modestly improved in those allocated ramipril during the trial with an 11% increase in regression

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

9. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study

The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study Lamy A, Wang X, Gao P, Tong W, Gafni A, Dans A, Avezum A, Ferreira R, Young J, Yusuf S, Teo K, ONTARGET Investigators Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to compare the costs for the angiotensin-receptor blocker (ARB), telmisartan, and the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in patients with vascular disease or high

NHS Economic Evaluation Database.2011

10. A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes

A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes Article Text Therapeutics A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes Statistics from Altmetric.com No Altmetric data available for this article. J F Mann

Evidence-Based Medicine (Requires free registration)2009

11. Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure

Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Article Text Causation Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Statistics from

Evidence-Based Nursing (Requires free registration)2008

12. Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes

Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes Article Text Therapeutics Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease

Evidence-Based Medicine (Requires free registration)2008

13. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. 18707986 2008 08 18 2008 08 25 2016 08 03 1474-547X 372 9638 2008 Aug 16 Lancet (London, England) Lancet Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. 547-53 10.1016/S0140-6736(08)61236-2 Angiotensin receptor (...) blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage. The trial ran from

Lancet2008

14. Telmisartan, ramipril, or both in patients at high risk for vascular events.

Telmisartan, ramipril, or both in patients at high risk for vascular events. 18378520 2008 04 11 2008 04 18 2014 01 09 1533-4406 358 15 2008 Apr 10 The New England journal of medicine N. Engl. J. Med. Telmisartan, ramipril, or both in patients at high risk for vascular events. 1547-59 10.1056/NEJMoa0801317 In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes (...) , but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes. After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy

NEJM2008

17. Effect of ramipril on the incidence of diabetes.

Effect of ramipril on the incidence of diabetes. 16980380 2006 10 12 2006 10 19 2016 08 03 1533-4406 355 15 2006 Oct 12 The New England journal of medicine N. Engl. J. Med. Effect of ramipril on the incidence of diabetes. 1551-62 Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with cardiovascular disease or hypertension. In a double-blind, randomized clinical trial with a 2-by-2 factorial design, we randomly assigned 5269 participants (...) without cardiovascular disease but with impaired fasting glucose levels (after an 8-hour fast) or impaired glucose tolerance to receive ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and followed them for a median of 3 years. We studied the effects of ramipril on the development of diabetes or death, whichever came first (the primary outcome), and on secondary outcomes, including regression to normoglycemia. The incidence of the primary outcome did not differ significantly

NEJM2006

18. Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective

Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective Cost effectiveness of ramipril in patients at high risk (...) drawn. Health technology The use of oral ramipril, given at 10 mg/day, for the treatment of patients with cardiovascular disease (CVD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients at high risk of cardiovascular events, who had the same characteristics as the patients included in the HOPE study. The HOPE inclusion criteria specified age 55 years or older and high risk

NHS Economic Evaluation Database.2004

19. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). 14960504 2004 02 27 2004 03 18 2014 06 09 1756-1833 328 7438 2004 Feb 28 BMJ (Clinical research ed.) BMJ Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo (...) controlled trial (the DIABHYCAR study). 495 To investigate whether a low dose of the angiotensin converting enzyme (ACE) inhibitor ramipril lowers cardiovascular and renal events in patients with type 2 diabetes who have microalbuminuria or proteinuria. Randomised, double blind, parallel group trial comparing ramipril (1.25 mg/day) with placebo (on top of usual treatment) for cardiovascular and renal outcomes for at least three years. Multicentre, primary care study conducted mostly by general

BMJ2004 Full Text: Link to full Text with Trip Pro

20. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study

Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study Smith M G, Neville A M, Middleton J C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The addition of ramipril (10 mg/day) to standard therapy, for the prevention of cardiovascular events in an at-risk population, was examined. Standard therapy included aspirin, cholesterol-lowering agents, beta-blockers, diuretics, calcium-channel blockers and oral hypoglycaemic agents. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.2003